Oncology

Overview

The Oncology research area is composed by nine groups addressing the principal unsolved issues in cancer. Their research covers fields such as child and adolescent cancer, melanoma, Gynecology, Urology, cancer stem cells and the molecular mechanisms of the tumor pathologies.

There are also three groups from the CIBBIM-Nanomedicine. These groups study the use of nanotechnology in biomedical applications to improve therapeutic strategies and diagnostics.

Publications

120

total

757.123

impact factor

6.309

average impact factor

Director: Santiago Ramon y Cajal Agu?eras

team

zoom

download

Combing pathology and molecular biology, the aim of our group is to unravel the molecular mechanisms in cancer progression and chemotherapeutic drug resistance. In this line, we continued our work on cellular stress resistance (Sese et al, Oncotarget), the identification of independent prognostic markers (Salcedo Allende MT, Pancreas) and the role of gap junctions in tumor progression (Aasen et al, Nature Reviews Cancer). Through our expertise in pathology, we could contribute to groundbreaking research in the field (e.g. Bullman S et al, Science). While maintaining our focus on tumor biology, we were moving forward to the field of tumor heterogeneity. In the coming years, we aim at using our privileged position of having the expertise and availability of primary tumors in the Pathology department and the molecular and cell biological expertise in the research group, to study the mechanisms underlying clonal cooperation in tumor progression and metastasis (Ramon y Cajal et al, BBA).

35

total

256^.540

impact factor

7^.330

average impact factor

SELECTED ARTICLES

Sesé M, Fuentes P, Esteve-Codina A, Béjar E, McGrail K, Thomas G, Aasen T, Ramón Y Cajal S.
Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-? signaling and malignant features in vitro and in vivo.
Oncotarget. 2017 Dec 12;8(70):114856-114876.
DOI: 10.18632/oncotarget.23145.
IF: 5,168
Ramón Y Cajal S, Capdevila C, Hernandez-Losa J, De Mattos-Arruda L, Ghosh A, Lorent J, Larsson O, Aasen T, Postovit LM, Topisirovic I.
Cancer as an ecomolecular disease and a neoplastic consortium.
Biochim Biophys Acta. 2017 Dec;1868(2):484-499.
DOI: 10.1016/j.bbcan.2017.09.004.
IF: 9,452
Salcedo Allende MT, Zeron-Medina J, Hernandez J, Macarulla T, Balsells J, Merino X, Allende H, Tabernero J, Ramon Y Cajal S.
Overexpression of Yes Associated Protein 1, an Independent Prognostic Marker in Patients With Pancreatic Ductal Adenocarcinoma, Correlated With Liver Metastasis and Poor Prognosis.
Pancreas. 2017 Aug;46(7):913-920.
DOI: 10.1097/MPA.0000000000000867.
IF: 2,967
Peg V, Sansano I, Vieites B, Bernet L, Cano R, Córdoba A, Sancho M, Martín MD, Vilardell F, Cazorla A, Espinosa-Bravo M, Pérez-García JM, Cortés J, Rubio IT, Ramón Y Cajal S.
Role of total tumour load of sentinel lymph node on survival in early breast cancer patients.
Breast. 2017 Jun;33:8-13.
DOI: 10.1016/j.breast.2017.02.011.
IF: 2,801
Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, Neuberg D, Huang K, Guevara F, Nelson T, Chipashvili O, Hagan T, Walker M, Ramachandran A, Diosdado B, Serna G, Mulet N, Landolfi S, Ramon Y Cajal S, Fasani R, Aguirre AJ, Ng K, Élez E, Ogino S, Tabernero J, Fuchs CS, Hahn WC, Nuciforo P, Meyerson M.
Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer.
Science. 2017 Dec 15;358(6369):1443-1448.
DOI: 10.1126/science.aal5240.
IF: 37.205

View all publications

Oncology

Overview

Publications

Director: Santiago Ramon y Cajal Agu?eras

Research Areas